The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus

Rodolfo Guardado-Mendoza, Annamaria Prioletta, Lilia M. Jiménez-Ceja, Aravind Sosale, Franco Folli

Research output: Contribution to journalArticle

54 Scopus citations


Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases worldwide, presenting a great challenge to the public health systems due to high morbidity and mortality, because of frequent micro-/macro-vascular complications. Many treatment options are now available, with different efficacy as well as mechanisms of action to improve deranged glucose metabolism. We review some of the available data on derivatives of meglitinide, namely nateglinide and repaglinide. These two compounds increase insulin secretion by a mechanism similar to the one of sulfonylureas, but with a shorter half-life. Nateglinide and repaglinide, derivatives of meglitinides, have characteristic pharmacodynamic and pharmacokinetic properties that, together with their proposed mechanism of action, make them useful for type 2 diabetes mellitus, especially when used in combination therapy.

Original languageEnglish (US)
Pages (from-to)936-943
Number of pages8
JournalArchives of Medical Science
Issue number5
Publication statusPublished - Oct 1 2013



  • Glycemic control
  • Hypoglycemia
  • Meglitinide
  • Nateglinide
  • Post-prandial glucose excursion
  • Repaglinide

ASJC Scopus subject areas

  • Medicine(all)

Cite this